APA (7th ed.) Citation

E, R., P, S., WE, B., JR, G., SL, P., CK, A., . . . GN, H. (2023). Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 24(2), 162. https://doi.org/10.1016/S1470-2045(22)00739-2

Chicago Style (17th ed.) Citation

E, Rodler, et al. "Cisplatin with Veliparib or Placebo in Metastatic Triple-negative Breast Cancer and BRCA Mutation-associated Breast Cancer (S1416): A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet. Oncology 24, no. 2 (2023): 162. https://doi.org/10.1016/S1470-2045(22)00739-2.

MLA (9th ed.) Citation

E, Rodler, et al. "Cisplatin with Veliparib or Placebo in Metastatic Triple-negative Breast Cancer and BRCA Mutation-associated Breast Cancer (S1416): A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet. Oncology, vol. 24, no. 2, 2023, p. 162, https://doi.org/10.1016/S1470-2045(22)00739-2.